Blood News and Research

RSS

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

Altor BioScience Corporation announced today that the National Heart Lung and Blood Institute has awarded Altor a Small Business Innovation Research Phase II Competing Renewal Grant. The award of over $3.18 MM over three years will support Altor's efforts to complete a second Phase 2 clinical trial using ALT-836, an antibody-based tissue factor antagonist, as a therapy to treat patients with infection-induced acute lung injury/acute respiratory distress syndrome.

24 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Novel hepatitis C-like virus discovered in dogs

In a study to be published online this week in the Proceedings of the National Academy of Sciences, researchers report the discovery of a novel hepatitis C-like virus in dogs. The identification and characterization of this virus gives scientists new insights into how hepatitis C in humans may have evolved and provides scientists renewed hope to develop a model system to study how it causes disease.

24 May 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

24 May 2011

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Researchers from Mount Sinai School of Medicine have discovered a protein signaling pathway that becomes hyperactivated in human sarcoma cells, suggesting that medications to inhibit this pathway may be effective in the treatment of human sarcomas. The research is published in the current issue of the journal Cancer Cell.

24 May 2011

'Survival protein' protects brain against effects of stroke

Johns Hopkins scientists say that a newly discovered "survival protein" protects the brain against the effects of stroke in rodent brain tissue by interfering with a particular kind of cell death that's also implicated in complications from diabetes and heart attack.

24 May 2011

African-Americans with multiple sclerosis have lower vitamin D levels

African-Americans who have multiple sclerosis have lower vitamin D levels than African-Americans who don't have the disease, according to a study published in the May 24, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

24 May 2011

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

The U.S. Food and Drug Administration today approved Incivek treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.

24 May 2011

Aptus EndoStapling System receives CE Mark approval

Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), announced CE Mark approval for the Aptus EndoStapling System. The innovative helical staple technology enables independent endograft fixation, and is designed to mimic the hand suturing performed during open surgical repair of abdominal aortic aneurysms.

From Medtronic 24 May 2011

Discovery of possible new strategy for treating neurologic disorders

23 May 2011

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company's lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels).

23 May 2011

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present the Aethlon ADAPT™ system in a presentation at the C21 BioVentures™ Life Sciences Partnering Conference.

23 May 2011

Lifestyle modifications help control blood pressure levels: More evidence

Evidence continues to build that lifestyle modifications help control blood pressure (BP) levels. Data evaluating the consumption of coffee and alcohol and the impact of low fitness levels will be presented at the American Society of Hypertension, Inc.'s 26th Annual Scientific Meeting and Exposition (ASH 2011) and will be featured in the May 22 ASH press briefing.

23 May 2011

Low doses of natural Hi-maize resistant starch could improve insulin sensitivity in men at risk for prediabetes

Low doses of natural Hi-maize resistant starch could improve insulin sensitivity in men at risk for prediabetes, according to a study underwritten by National Starch LLC, a business unit of Corn Products International. The American Diabetes Association defines prediabetes as a non-disease state where blood sugar (glucose) levels are higher than normal, but not yet high enough to be diagnosed as diabetes.

23 May 2011

Nano-complex pre-meal dietary supplement can reduce fat and sugar absorption in the body

A little bitter with a little sweet, in the form of a nano-complex dietary supplement taken before meals, can result in a substantial reduction of fat and sugar absorption in the body, Hebrew University of Jerusalem and Harvard University researchers have found.

23 May 2011

New technique can detect minute traces of tumoral DNA in biological fluids

It will perhaps be possible, in the near future, to detect cancer by a simple blood or urine test. In fact, biologists from CNRS, Inserm, Paris Descartes and Strasbourg universities have developed a technique capable of detecting minute traces of tumoral DNA present in the biological fluids of patients suffering from cancer.

23 May 2011

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood.

23 May 2011

Lund University researcher discovers new sepsis biomarker in blood

Sepsis is the name of an infection that causes a series of reactions in the body, which in the worst case can prove fatal. The problem for both patients and doctors is that the early symptoms are difficult to distinguish from less dangerous infections such as a severe flu or winter vomiting disease.

23 May 2011

Novel compound could become an effective alternative to common narcotic analgesics

Scientists from the Florida campus of The Scripps Research Institute have for the first time accomplished a laboratory synthesis of a rare natural product isolated from the bark of a plant widely employed in traditional medicine.

23 May 2011

Roche's new cobas TaqScreen MPX viral discriminatory test, v2.0 now available in Europe

Roche announced today that the cobas TaqScreen MPX Test, version 2.0 for use on the cobas s 201 system is now commercially available in Europe.

23 May 2011

Blood News and Research

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Novel hepatitis C-like virus discovered in dogs

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

'Survival protein' protects brain against effects of stroke

African-Americans with multiple sclerosis have lower vitamin D levels

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

Aptus EndoStapling System receives CE Mark approval

Discovery of possible new strategy for treating neurologic disorders

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Lifestyle modifications help control blood pressure levels: More evidence

Low doses of natural Hi-maize resistant starch could improve insulin sensitivity in men at risk for prediabetes

Nano-complex pre-meal dietary supplement can reduce fat and sugar absorption in the body

New technique can detect minute traces of tumoral DNA in biological fluids

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Lund University researcher discovers new sepsis biomarker in blood

Novel compound could become an effective alternative to common narcotic analgesics

Roche's new cobas TaqScreen MPX viral discriminatory test, v2.0 now available in Europe

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News